Language:

The Potential Role of Fibroblast Growth Factor 21 in Lipid Metabolism and Hypertension

Current hypertension reports, 2017-04, Vol.19 (4), p.28-28, Article 28 [Peer Reviewed Journal]

Springer Science+Business Media New York 2017 ;Current Hypertension Reports is a copyright of Springer, 2017. ;ISSN: 1522-6417 ;EISSN: 1534-3111 ;DOI: 10.1007/s11906-017-0730-5 ;PMID: 28337713

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
The Potential Role of Fibroblast Growth Factor 21 in Lipid Metabolism and Hypertension
Author: Huang, Zhe ; Xu, Aimin ; Cheung, Bernard M. Y.
Subjects: Animals ; Blood pressure ; Cardiology ; Diabetes Mellitus, Type 2 - metabolism ; Family Medicine ; Fatty Liver - metabolism ; Fibroblast Growth Factors - metabolism ; Fibroblasts ; General Practice ; Growth factors ; Humans ; Hypertension ; Hypertension - drug therapy ; Hypertension - metabolism ; Hypertension and Metabolic Syndrome (J Sperati ; Internal Medicine ; Lipid Metabolism ; Male ; Medicine ; Medicine & Public Health ; Metabolic Diseases ; Metabolism ; Nephrology ; Obesity - metabolism ; Primary Care Medicine ; Rodents ; Section Editor ; Topical Collection on Hypertension and Metabolic Syndrome
Is Part Of: Current hypertension reports, 2017-04, Vol.19 (4), p.28-28, Article 28
Description: Fibroblast growth factor (FGF) 21 belongs to the FGF superfamily that is involved in cell proliferation and differentiation, neural development, angiogenesis, and metabolism. FGF21 requires β-Klotho as a co-receptor. Tissues involved in metabolism such as the liver, adipose tissues, skeletal muscle, and pancreas express FGF21. Starvation increases hepatic expression of FGF21, which then acts centrally to increase hepatic gluconeogenesis. FGF21 also increases fatty acid oxidation. This may be relevant in cold exposure, when expression of FGF21 is induced. Chronic treatment with recombinant FGF21 reduces serum and hepatic triglyceride levels and ameliorates fatty liver in obese mice, through the suppression of the lipogenic gene, Srebp-1 . FGF21 reduces hepatic cholesterol production by inhibiting Srebp-2 , a transactivator of proprotein convertase subtilisin/kexin type 9 (PCSK9). LY2045319, an FGF21 analog, reduces LDL-C and triglycerides and increases HDL-C in obese human subjects with type 2 diabetes. FGF21 does not seem to lower blood pressure acutely. In rats fed with high-fructose water to induce mild hypertension, 4-week treatment with recombinant FGF21 led to normalization of systolic blood pressure and improved serum lipid profile. FGF receptors and β-Klotho are expressed on the nucleus tractus solitarii and nodose ganglion in the baroreflex afferent pathway. Moreover, FGF21 acts on the hypothalamus to release corticosterone and induces in adipocytes the production of adiponectin, an adipokine with antihypertensive activities. Therefore, FGF21 may decrease blood pressure indirectly, through its actions in the liver, brain, and adipose tissues.
Publisher: New York: Springer US
Language: English
Identifier: ISSN: 1522-6417
EISSN: 1534-3111
DOI: 10.1007/s11906-017-0730-5
PMID: 28337713
Source: MEDLINE
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

The Potential Role of Fibroblast Growth Factor 21 in Lipid Metabolism and Hypertension

Springer Science+Business Media New York 2017 ;Current Hypertension Reports is a copyright of Springer, 2017. ;ISSN: 1522-6417 ;EISSN: 1534-3111 ;DOI: 10.1007/s11906-017-0730-5 ;PMID: 28337713

Searching Remote Databases, Please Wait